Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy

Abstract

Objectives To determine the recommended dose and efficacy/safety of docetaxel combined with resminostat (DR) in non-small cell lung cancer (NSCLC) patients with previous platinum-based chemotherapy. Materials and Methods A multicenter, open-label, phase I/II study was performed in Japanese patients with stage IIIB/IV or recurrent NSCLC and prior platinum-based chemotherapy. The recommended phase II dose was determined using a standard 3 + 3 dose design in phase I part. Resminostat was escalated from 400 to 600 mg/day and docetaxel fixed at 75 mg/m. In phase II part, the patients were randomly assigned to docetaxel alone (75 mg/m) or DR therapy. Docetaxel was administered on day 1 and resminostat on days 1-5 in the DR group. Treatment was repeated every 21 days until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Results A total of 117 patients (phase I part, 9; phase II part, 108) were enrolled. There was no dose-limiting toxicity in phase I part; the recommended dose for resminostat was 600 mg/day with 75 mg/m of docetaxel. In phase II part, median PFS (95% confidence interval [CI]) was 4.2 (2.8-5.7) months with docetaxel group and 4.1 (1.5-5.4) months with DR group (hazard ratio [HR]: 1.354, 95% CI: 0.835-2.195; p = 0.209). Grade ≥ 3 adverse events significantly more common with DR group than docetaxel group were leukopenia, febrile neutropenia, thrombocytopenia, and anorexia. Conclusion In Japanese NSCLC patients previously treated with platinum-based chemotherapy, DR therapy did not improve PFS compared with docetaxel alone and increased toxicity.

The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma

“…A major hurdle for translating this observation into therapy, however, comes from the multitude of proteins involved in this epigenetic machinery. This seemingly overlapping and partially redundant role is probably one of the causes why prior trials using Histone Deacetylase inhibitors (HDACi) in solid cancers, including GBM, have not been successful at prolonging survival 43,44 . Furthermore, recent evidence suggests that co-downregulation of multiple such epigenetic pathways, including BMI1 and EZH2, is needed to obtain a significant biological effect in cancer cells 22,31 .…”

The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma

“…Previously tested in Phase I or II studies in patients with hepatocellular carcinoma, Hodgkin lymphoma, biliary tract and pancreatic cancer, and non‐small cell lung cancer 86,92,93,95 …”

Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer

“…In human patients with advanced solid tumors, an investigation on Resminostat was carried out to study its safety and tolerability. It was found to be safely administered and to have anticancer effects with a dose-proportional pharmacokinetic profile (Tambo et al, 2017). Resminostat is also used with the combination of other drugs for better efficacy like sorafenib and docetaxel (Bitzer et al, 2016; Mandl-Weber et al, 2010).…”